메뉴 건너뛰기




Volumn 73, Issue 3, 2018, Pages 564-568

MIC-based dose adjustment: Facts and fables

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIAL GROWTH; BIOLOGICAL VARIATION; CLINICAL LABORATORY; CLINICAL PRACTICE; DRUG MONITORING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; SPECIES IDENTIFICATION; STAPHYLOCOCCUS AUREUS; BACTERIUM; DOSE RESPONSE; DRUG EFFECT; MICROBIAL SENSITIVITY TEST; PROCEDURES; REPRODUCIBILITY; STANDARDS;

EID: 85043324373     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkx427     Document Type: Article
Times cited : (241)

References (24)
  • 1
    • 85016493892 scopus 로고    scopus 로고
    • Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy
    • Economou CJP, Wong G, McWhinney B et al. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2017; 49: 589-94.
    • (2017) Int J Antimicrob Agents , vol.49 , pp. 589-594
    • Economou, C.J.P.1    Wong, G.2    McWhinney, B.3
  • 2
    • 84981156383 scopus 로고    scopus 로고
    • The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France
    • Charmillon A, Novy E, Agrinier N et al. The ANTIBIOPERF study: a nationwide cross-sectional survey about practices for β-lactam administration and therapeutic drug monitoring among critically ill patients in France. Clin Microbiol Infect 2016; 22: 625-31.
    • (2016) Clin Microbiol Infect , vol.22 , pp. 625-631
    • Charmillon, A.1    Novy, E.2    Agrinier, N.3
  • 3
    • 84898474668 scopus 로고    scopus 로고
    • An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units
    • Wong G, Brinkman A, Benefield RJ et al. An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units. J Antimicrob Chemother 2014; 69: 1416-23.
    • (2014) J Antimicrob Chemother , vol.69 , pp. 1416-1423
    • Wong, G.1    Brinkman, A.2    Benefield, R.J.3
  • 4
    • 84963511132 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of anti-infective agents in critically ill patients
    • Jager NG, van Hest RM, Lipman J et al. Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Rev Clin Pharmacol 2016; 9: 961-79.
    • (2016) Expert Rev Clin Pharmacol , vol.9 , pp. 961-979
    • Jager, N.G.1    van Hest, R.M.2    Lipman, J.3
  • 6
    • 13244281964 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration
    • Mouton JW, Vinks AA. Pharmacokinetic/pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin Pharmacokinet 2005; 44: 201-10.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 201-210
    • Mouton, J.W.1    Vinks, A.A.2
  • 7
    • 0030009518 scopus 로고    scopus 로고
    • Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model
    • Bouvier d'Yvoire MJY, Maire PH. Dosage regimens of antibacterials. Implications of a pharmacokinetic/pharmacodynamic model. Clin Drug Investig 1996; 11: 229-39.
    • (1996) Clin Drug Investig , vol.11 , pp. 229-239
    • Bouvier d'Yvoire, M.J.Y.1    Maire, P.H.2
  • 8
    • 22244490051 scopus 로고    scopus 로고
    • Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations
    • Mouton JW, Vinks AA. Relationship between minimum inhibitory concentration and stationary concentration revisited: growth rates and minimum bactericidal concentrations. Clin Pharmacokinet 2005; 44: 767-8.
    • (2005) Clin Pharmacokinet , vol.44 , pp. 767-768
    • Mouton, J.W.1    Vinks, A.A.2
  • 11
    • 0041527129 scopus 로고    scopus 로고
    • European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria
    • Kahlmeter G, Brown DF, Goldstein FW et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. JAntimicrobChemother 2003; 52: 145-8.
    • (2003) JAntimicrobChemother , vol.52 , pp. 145-148
    • Kahlmeter, G.1    Brown, D.F.2    Goldstein, F.W.3
  • 12
    • 84953418008 scopus 로고    scopus 로고
    • The 2014 Garrod Lecture: EUCAST-are we heading towards international agreement?
    • Kahlmeter G. The 2014 Garrod Lecture: EUCAST-are we heading towards international agreement? J Antimicrob Chemother 2015; 70: 2427-39.
    • (2015) J Antimicrob Chemother , vol.70 , pp. 2427-2439
    • Kahlmeter, G.1
  • 13
    • 0031952586 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men
    • Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
    • (1998) Clin Infect Dis , vol.26 , pp. 1-12
    • Craig, W.A.1
  • 14
    • 33845696211 scopus 로고    scopus 로고
    • Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    • Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
    • (2007) Clin Infect Dis , vol.44 , pp. 79-86
    • Ambrose, P.G.1    Bhavnani, S.M.2    Rubino, C.M.3
  • 15
    • 84964296722 scopus 로고    scopus 로고
    • Applying pharmacokinetic/ pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development
    • Abdul-Aziz MH, Lipman J, Mouton JW et al. Applying pharmacokinetic/ pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med 2015; 36: 136-53.
    • (2015) Semin Respir Crit Care Med , vol.36 , pp. 136-153
    • Abdul-Aziz, M.H.1    Lipman, J.2    Mouton, J.W.3
  • 16
    • 84901006498 scopus 로고    scopus 로고
    • Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions
    • Roberts JA, Abdul-Aziz MH, Lipman J et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 2014; 14: 498-509.
    • (2014) Lancet Infect Dis , vol.14 , pp. 498-509
    • Roberts, J.A.1    Abdul-Aziz, M.H.2    Lipman, J.3
  • 17
    • 72249093367 scopus 로고    scopus 로고
    • Augmented renal clearance: implications for antibacterial dosing in the critically ill
    • Udy AA, Roberts JA, Boots RJ et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
    • (2010) Clin Pharmacokinet , vol.49 , pp. 1-16
    • Udy, A.A.1    Roberts, J.A.2    Boots, R.J.3
  • 18
    • 69949103098 scopus 로고    scopus 로고
    • Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the newtransmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions
    • Cavaco LM, Aarestrup FM. Evaluation of quinolones for use in detection of determinants of acquired quinolone resistance, including the newtransmissible resistance mechanisms qnrA, qnrB, qnrS, and aac(6')Ib-cr, in Escherichia coli and Salmonella enterica and determinations of wild-type distributions. J ClinMicrobiol 2009; 47: 2751-8.
    • (2009) J ClinMicrobiol , vol.47 , pp. 2751-2758
    • Cavaco, L.M.1    Aarestrup, F.M.2
  • 19
    • 68549132348 scopus 로고    scopus 로고
    • Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species
    • Kohner PC, Robberts FJ, Cockerill FR 3rd et al. Cephalosporin MIC distribution of extended-spectrum-β-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species. J ClinMicrobiol 2009; 47: 2419-25.
    • (2009) J ClinMicrobiol , vol.47 , pp. 2419-2425
    • Kohner, P.C.1    Robberts, F.J.2    Cockerill, F.R.3
  • 20
    • 84945176706 scopus 로고    scopus 로고
    • Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant Salmonella enterica
    • Skov R, Matuschek E, Sjölund-Karlsson M et al. Development of a pefloxacin disk diffusion method for detection of fluoroquinolone-resistant Salmonella enterica. JClinMicrobiol 2015; 53: 3411-7.
    • (2015) JClinMicrobiol , vol.53 , pp. 3411-3417
    • Skov, R.1    Matuschek, E.2    Sjölund-Karlsson, M.3
  • 21
    • 85043325004 scopus 로고    scopus 로고
    • EUCAST. https://mic.eucast.org/Eucast2/.
  • 22
    • 67651083250 scopus 로고    scopus 로고
    • Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists
    • Rybak MJ, Lomaestro BM, Rotschafer JC et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49: 325-7.
    • (2009) Clin Infect Dis , vol.49 , pp. 325-327
    • Rybak, M.J.1    Lomaestro, B.M.2    Rotschafer, J.C.3
  • 23
    • 84949026642 scopus 로고    scopus 로고
    • Therapeutic drug monitoring of the β-lactamantibiotics: what is the evidence and which patients should we be using it for?
    • Huttner A, Harbarth S, Hope WW et al. Therapeutic drug monitoring of the β-lactamantibiotics: what is the evidence and which patients should we be using it for? J Antimicrob Chemother 2015; 70: 3178-83.
    • (2015) J Antimicrob Chemother , vol.70 , pp. 3178-3183
    • Huttner, A.1    Harbarth, S.2    Hope, W.W.3
  • 24
    • 0036736403 scopus 로고    scopus 로고
    • Pharmacodynamics of cefepime in patients with Gram-negative infections
    • Tam VH, McKinnon PS, Akins RL et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 2002; 50: 425-8.
    • (2002) J Antimicrob Chemother , vol.50 , pp. 425-428
    • Tam, V.H.1    McKinnon, P.S.2    Akins, R.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.